Glucagon-like Peptide 1 Receptor Signaling in Acinar Cells Causes Growth-Dependent Release of Pancreatic Enzymes
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Incretin-based therapies are widely used for type 2 diabetes and now also for obesity, but they are associated with elevated plasma levels of pancreatic enzymes and perhaps a modestly increased risk of acute pancreatitis. However, little is known about the effects of the incretin hormone glucagon-like peptide 1 (GLP-1) on the exocrine pancreas. Here, we identify GLP-1 receptors on pancreatic acini and analyze the impact of receptor activation in humans, rodents, isolated acini, and cell lines from the exocrine pancreas. GLP-1 did not directly stimulate amylase or lipase release. However, we saw that GLP-1 induces phosphorylation of the epidermal growth factor receptor and activation of Foxo1, resulting in cell growth with concomitant enzyme release. Our work uncovers GLP-1-induced signaling pathways in the exocrine pancreas and suggests that increases in amylase and lipase levels in subjects treated with GLP-1 receptor agonists reflect adaptive growth rather than early-stage pancreatitis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577 · cited 1×
“…(which elevate levels of endogenous GLP-1), all showing non-significant changes in acute pancreatitis rates as compared to placebo treatment control groups, albeit with a numerical imbalance in some studies (Scirica et al., 2013; White et al., 2013; Green et al., 2015; Bentley-Lewis et al., 2015).”
ResultAlogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502 · cited 1×
“…(which elevate levels of endogenous GLP-1), all showing non-significant changes in acute pancreatitis rates as compared to placebo treatment control groups, albeit with a numerical imbalance in some studies (Scirica et al., 2013; White et al., 2013; Green et al., 2015; Bentley-Lewis et al., 2015).”
ResultDavies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198 · cited 1×
“…of a clear relationship is supported by large-scale randomized studies with liraglutide (most recently by the LEADER study) (Pi-Sunyer et al., 2015; Davies et al., 2015; Marso et al., 2016) published after the FDA/EMA report, as well as other large cardiovascular safety outcome studies with GLP-1…”
ResultBan, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 1×
“Moreover, since the predominant circulating form of endogenous GLP-1 is the N-terminally truncated product of DPP-4 action, GLP-1 9-36 NH 2 (Deacon et al., 1995), which may share some effects with GLP-1 (Ban et al., 2008), we also examined the effects of this peptide at relevant doses.”
BackgroundPancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944 · cited 1×
“Their pancreatic safety has been under intense debate (Meier and Nauck, 2014; Butler et al., 2013; Elashoff et al., 2011; Egan et al., 2014), since their use has been associated with sporadic cases of acute pancreatitis and generally mildly elevated levels of markers of this disease (amylase and…”
BackgroundPyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014) · Endocrinology · doi:10.1210/en.2013-1934 · Cited by 876 · cited 1×
“Using a well-characterized and validated GLP-1 receptor (GLP-1R) antibody (Pyke et al., 2014), we demonstrated GLP-1R expression in pancreatic acinar cells (positive staining for amylase), which was missing in tissue biopsy specimens from GLP-1R knockout mice (Figure 1C).”
BackgroundDeacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792 · cited 1×
“Moreover, since the predominant circulating form of endogenous GLP-1 is the N-terminally truncated product of DPP-4 action, GLP-1 9-36 NH 2 (Deacon et al., 1995), which may share some effects with GLP-1 (Ban et al., 2008), we also examined the effects of this peptide at relevant doses.”
BackgroundSelf-citationPancreatic safety of incretin-based drugs–FDA and EMA assessment
Egan, A. G., Blind, E., Dunder, K., de Graeff, P. A., Hummer, B. T., Bourcier, T., & Rosebraugh, C. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1314078 · Cited by 498
A Critical Analysis of the Clinical Use of Incretin-Based Therapies
Butler, P. C., Elashoff, M., Elashoff, R., & Gale, E. A. M. (2013) · Diabetes Care · doi:10.2337/dc12-2713 · Cited by 296 · cited 2×
“Their pancreatic safety has been under intense debate (Meier and Nauck, 2014; Butler et al., 2013; Elashoff et al., 2011; Egan et al., 2014), since their use has been associated with sporadic cases of acute pancreatitis and generally mildly elevated levels of markers of this disease (amylase and…”
BackgroundGier, B., Matveyenko, A. V., Kirakossian, D., Dawson, D., Dry, S. M., & Butler, P. C. (2012) · Diabetes · doi:10.2337/db11-1109 · Cited by 255
Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas
Nachnani, J. S., Bulchandani, D. G., Nookala, A., Herndon, B., Molteni, A., Pandya, P., Taylor, R., Quinn, T., Weide, L., & Alba, L. M. (2010) · Diabetologia · doi:10.1007/s00125-009-1515-4 · Cited by 189 · cited 2×
“These results regarding GLP-1-induced proliferation are consistent with other data obtained in mice (Ellenbroek et al., 2013), rats (Perfetti et al., 2000; Gier et al., 2012; Nachnani et al., 2010), and monkeys (Nyborg et al., 2012).”
BackgroundResultTranscription factor FoxO1 mediates glucagon-like peptide-1 effects on pancreatic β-cell mass
Buteau, J., Spatz, M. L., & Accili, D. (2006) · Diabetes · doi:10.2337/db05-0825 · Cited by 178 · cited 1×
“We therefore tested whether GLP-1-induced cell proliferation was mediated by c-Src/EGFR related pathways (c-Src, epidermal growth factor receptor [EGFR], phosphatidylinositol 3-kinase [PI3K], and Foxo1), as reported for pancreatic b cells (Buteau et al., 2006).”
BackgroundJensen, E. P., Poulsen, S. S., Kissow, H., Holstein-Rathlou, N.-H., Deacon, C. F., Jensen, B. L., Holst, J. J., & Sorensen, C. M. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00527.2014 · Cited by 141 · cited 2×
“Autoradiography was performed using (125)I-labeled EX9-39 as described previously (Jensen et al., 2015).”
MethodSelf-citationThe Human GLP-1 Analog Liraglutide and the Pancreas
Nyborg, N. C. B., Mølck, A.-M., Madsen, L. W., & Bjerre Knudsen, L. (2012) · Diabetes · doi:10.2337/db11-0936 · Cited by 125 · cited 1×
“These results regarding GLP-1-induced proliferation are consistent with other data obtained in mice (Ellenbroek et al., 2013), rats (Perfetti et al., 2000; Gier et al., 2012; Nachnani et al., 2010), and monkeys (Nyborg et al., 2012).”
ResultIncretin based drugs and the risk of pancreatic cancer: international multicentre cohort study
Azoulay, L., Filion, K. B., Platt, R. W., Dahl, M., Dormuth, C. R., Clemens, K. K., Durand, M., Juurlink, D. N., Targownik, L. E., Turin, T. C., et al. (2016) · BMJ · doi:10.1136/bmj.i581 · Cited by 120
Risk of pancreatitis in patients treated with incretin-based therapies
Meier, J. J., & Nauck, M. A. (2014) · Diabetologia · doi:10.1007/s00125-014-3231-y · Cited by 101
Glucagon-like peptide-1 receptor agonist treatment reduces beta cell mass in normoglycaemic mice
Ellenbroek, J. H., Töns, H. A. M., Westerouen van Meeteren, M. J. A., de Graaf, N., Hanegraaf, M. A., Rabelink, T. J., Carlotti, F., & de Koning, E. J. P. (2013) · Diabetologia · doi:10.1007/s00125-013-2957-2 · Cited by 43
Smits, M. M., Tonneijck, L., Muskiet, M. H. A., Diamant, M., Kramer, M. H. H., Cahen, D. L., & van Raalte, D. H. (2017) · Diabetic Medicine · doi:10.1111/dme.13160 · Cited by 7
Cited by
Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
McLean, B. A., Wong, C. K., Campbell, J. E., Hodson, D. J., Trapp, S., & Drucker, D. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa032 · Cited by 289
Mu, Y., Bao, X., Eliaschewitz, F. G., Hansen, M. R., Kim, B. T., Koroleva, A., Ma, R. C. W., Yang, T., Zu, N., & Liu, M. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00388-1 · Cited by 133
Andersen, D. B., Grunddal, K. V., Pedersen, J., Kuhre, R. E., Lund, M. L., Holst, J. J., & Ørskov, C. (2021) · Endocrinology · doi:10.1210/endocr/bqaa246 · Cited by 54
Self-citation
Metadata
- Authors
- Wewer Albrechtsen, N. J., Albrechtsen, R., Bremholm, L., Svendsen, B., Kuhre, R. E., Poulsen, S. S., Christiansen, C. B., Jensen, E. P., Janus, C., Hilsted, L., Deacon, C. F., Hartmann, B., & Holst, J. J.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2016-12
- Volume
- 17
- Issue
- 11
- Pages
- 2845-2856
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W2563028159
- Cited by
- 40
- References
- 21
- FWCI
- 3.46
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.